These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30477570)

  • 1. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
    Méndez-Vidal MJ; Molina Á; Anido U; Chirivella I; Etxaniz O; Fernández-Parra E; Guix M; Hernández C; Lambea J; Montesa Á; Pinto Á; Ros S; Gallardo E
    BMC Pharmacol Toxicol; 2018 Nov; 19(1):77. PubMed ID: 30477570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
    Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
    Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
    Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
    BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
    Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
    Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.
    Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C
    Clin Genitourin Cancer; 2019 Feb; 17(1):e150-e155. PubMed ID: 30396828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.
    Bersanelli M; Facchinetti F; Tiseo M; Maiorana M; Buti S
    Curr Drug Targets; 2016; 17(15):1755-1760. PubMed ID: 26758665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
    Frampton JE
    Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.